In our data, the incidence of MET amplification was 0.79% (23/2,927) in all types of lung cancers, 0.78% (21/2,676) in adenocarcinoma and 1.07% (2/187) in squamous cell carcinoma, with no MET amplification in other histology types. This evidence concerns the gene MET and lung carcinoma.